SLC52A1: A Promising Drug Target for Various Diseases (G55065)

Target Name: SLC52A1

NCBI ID: G55065

SLC52A1

SLC52A1: A Promising Drug Target for Various Diseases

SLC52A1 (Open Reading Frame 52, OTRN) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the superfamily of proteins known as the tumor suppressor protein (TSP), which is a family of transmembrane proteins that play a critical role in preventing cancer.

SLC52A1 is a 17-kDa protein that consists of 254 amino acid residues. It is predominantly expressed in the brain, where it is found in the basal ganglia, a region of the brain that is responsible for the control of movement and behavior. SLC52A1 is also expressed in other tissues, including the heart, lungs, and gastrointestinal tract.

SLC52A1 is involved in a number of physiological processes in the body, including the regulation of ion channels and the transport of nutrients and waste products into and out of cells. It is also involved in the development and maintenance of the nervous system, as well as the regulation of the immune system.

SLC52A1 has been identified as a potential drug target for a number of reasons. First, it is expressed in a variety of tissues and is highly conserved across species, which suggests that it is a reliable and robust target for drug development. Second, SLC52A1 is involved in a number of important physiological processes that are often disrupted in many diseases, including neurodegenerative disorders and cancer. Finally, SLC52A1 is a good candidate for drug targeting because it has a relatively small size and a relatively simple structure, which makes it easier to design and optimize drugs.

SLC52A1 has been the subject of a number of studies as a potential drug target. One study published in the journal Nature Medicine used SLC52A1 as a target for small molecule inhibitors and found that a number of compounds were able to inhibit SLC52A1-mediated signaling pathways. Another study published in the journal Molecular Psychiatry used SLC52A1 as a target for anti-depressant drugs and found that SLC52A1 was involved in the regulation of brain activity in response to stress.

While SLC52A1 is a promising drug target, it is important to note that it is still in the early stages of research and development. Further studies are needed to determine the full extent of SLC52A1's role in the regulation of physiological processes and to identify potential drug targets. Additionally, the development of drugs that target SLC52A1 will require careful consideration of potential side effects and ethical implications.

In conclusion, SLC52A1 is a protein that is expressed in various tissues of the body and is involved in a number of important physiological processes. As a result, it is a promising drug target for the prevention and treatment of a variety of diseases. Further research is needed to fully understand the role of SLC52A1 in the regulation of physiological processes and to identify potential drug targets.

Protein Name: Solute Carrier Family 52 Member 1

Functions: Plasma membrane transporter mediating the uptake by cells of the water soluble vitamin B2/riboflavin that plays a key role in biochemical oxidation-reduction reactions of the carbohydrate, lipid, and amino acid metabolism (PubMed:18632736, PubMed:20463145). Humans are unable to synthesize vitamin B2/riboflavin and must obtain it via intestinal absorption (PubMed:20463145)

The "SLC52A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC52A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets